A general procedure to select calibration drugs for lab-specific validation and calibration of proarrhythmia risk prediction models: An illustrative example using the CiPA model
Authors:
Open Access
- 1 September 2020
- journal article
- research article
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 105, 106890
Abstract
No abstract availableKeywords
Funding Information
- Research Participation Program at the Center for Drug Evaluation and Research
- Oak Ridge Institute for Science and Education
- US Department of Energy
- US Food and Drug Administration
This publication has 22 references indexed in Scilit:
- Evolution of strategies to improve preclinical cardiac safety testingNature Reviews Drug Discovery, 2016
- A new classifier-based strategy for in-silico ion-channel cardiac drug safety assessmentFrontiers in Pharmacology, 2015
- Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessmentJournal of Pharmacological and Toxicological Methods, 2013
- MICE Models: Superior to the HERG Model in Predicting Torsade de PointesScientific Reports, 2013
- Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37°C: Cisapride versus dofetilideJournal of Pharmacological and Toxicological Methods, 2010
- hERG in vitro interchange factors—development and verificationToxicology Mechanisms and Methods, 2009
- Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmiasHeart Rhythm, 2006
- Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibresBritish Journal of Pharmacology, 2005
- PCR-based Calibration Curves for Studies of Quantitative Gene Expression in Human Monocytes: Development and EvaluationClinical Chemistry, 2003
- Properties of HERG Channels Stably Expressed in HEK 293 Cells Studied at Physiological TemperatureBiophysical Journal, 1998